From: Data-driven translational prostate cancer research: from biomarker discovery to clinical decision
Name | Type | Description | PMID |
---|---|---|---|
Image features | |||
 Zinc-Specific iCEST MRI | Diagnosis | Differentiating normal and malignant prostate cells with a high fold-change | 31430007 |
 DCE-MRI | Prognosis | Reflecting PCa microcirculation and showing correlation with PSA and clinical stage | 30327584 |
 DWI signal | Prognosis | Providing information for bone metastasis and treatment of mCRPC | 28906339 |
 DWI signal | Therapy | Monitoring changes in response to androgen deprivation therapy in PCa patients | 25415730 |
 FLT PET/CT | Therapy | Predicting progression-free survival and promoting immunotherapy for mPCa patients | 30700328 |
 PSMA-derived volumetric parameters | Therapy | Evaluating whole-body tumor burden and facilitating therapy monitoring for mPCa | 28522740 |
 BSI | Prognosis | Predicting the survival time of mCRPC patients treated with Abiraterone Acetate | 28723520 |
 aBSI | Prognosis | Predicting the overall survival of patients with mCRPC | 29799999 |
 BSI, ΔBSI | Prognosis | Predicting poor overall survival and cancer specific survival | 29137438 |
Clinical symptoms | |||
 Lower urinary tract symptoms | Diagnosis | The symptoms increase the attention of physicians for PCa diagnosis | 23313032 |
 Lower urinary tract symptoms | Therapy | The changes are associated with the responses to salvage radiotherapy for biochemical recurrence of PCa | 25991382 |
 Urinary problems, fatigue | Therapy | Predicting health-related quality of life in PCa patients with localized radiation therapy | 30263893 |
 Sexual dysfunction | Therapy | This symptom may be caused by the therapy of M0-CRPC | 28285412 |
 Depression | Therapy | The severity is positively correlated with the duration of androgen deprivation therapy | 30651026 |